TGF-β trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistance
At the ASCO 2024 meeting, Anthony P Conley, coauthor on this editorial, presented promising data from the phase 1/2 clinical trial called BETA PRIME (ClinicalTrials.gov NCT04673942) with AdAPT-001 plus a checkpoint inhibitor (CI). All participants gave informed consent to participate in BETA PRIME b...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2024-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/12/10/e009613.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850193719949524992 |
|---|---|
| author | Anthony Conley Jeannie Williams Bryan Oronsky Tony R Reid Scott Caroen |
| author_facet | Anthony Conley Jeannie Williams Bryan Oronsky Tony R Reid Scott Caroen |
| author_sort | Anthony Conley |
| collection | DOAJ |
| description | At the ASCO 2024 meeting, Anthony P Conley, coauthor on this editorial, presented promising data from the phase 1/2 clinical trial called BETA PRIME (ClinicalTrials.gov NCT04673942) with AdAPT-001 plus a checkpoint inhibitor (CI). All participants gave informed consent to participate in BETA PRIME before taking part. AdAPT-001 is an oncolytic adenovirus that expresses a transforming growth factor beta (TGF-β) trap to neutralize active TGF-β. This editorial proposes that the TGF-β trap of AdAPT-001 reverses the immunosuppressive environment of tumor cells, and thus makes these tumors susceptible to CIs like the anti-PD-1 agent, nivolumab, and potentially other therapies as well. |
| format | Article |
| id | doaj-art-aecf5422aa754638a2ebd465ca8a0081 |
| institution | OA Journals |
| issn | 2051-1426 |
| language | English |
| publishDate | 2024-10-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-aecf5422aa754638a2ebd465ca8a00812025-08-20T02:14:11ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262024-10-01121010.1136/jitc-2024-009613TGF-β trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistanceAnthony Conley0Jeannie Williams1Bryan Oronsky2Tony R Reid3Scott Caroen4Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA3EpicentRx, La Jolla, CA, USA3EpicentRx, La Jolla, CA, USAEpicentRx Inc, La Jolla, California, USA4EpicentRx, San Diego, CA, USAAt the ASCO 2024 meeting, Anthony P Conley, coauthor on this editorial, presented promising data from the phase 1/2 clinical trial called BETA PRIME (ClinicalTrials.gov NCT04673942) with AdAPT-001 plus a checkpoint inhibitor (CI). All participants gave informed consent to participate in BETA PRIME before taking part. AdAPT-001 is an oncolytic adenovirus that expresses a transforming growth factor beta (TGF-β) trap to neutralize active TGF-β. This editorial proposes that the TGF-β trap of AdAPT-001 reverses the immunosuppressive environment of tumor cells, and thus makes these tumors susceptible to CIs like the anti-PD-1 agent, nivolumab, and potentially other therapies as well.https://jitc.bmj.com/content/12/10/e009613.full |
| spellingShingle | Anthony Conley Jeannie Williams Bryan Oronsky Tony R Reid Scott Caroen TGF-β trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistance Journal for ImmunoTherapy of Cancer |
| title | TGF-β trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistance |
| title_full | TGF-β trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistance |
| title_fullStr | TGF-β trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistance |
| title_full_unstemmed | TGF-β trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistance |
| title_short | TGF-β trap of AdAPT-001 turns up the heat on tumors and turns down checkpoint blocker resistance |
| title_sort | tgf β trap of adapt 001 turns up the heat on tumors and turns down checkpoint blocker resistance |
| url | https://jitc.bmj.com/content/12/10/e009613.full |
| work_keys_str_mv | AT anthonyconley tgfbtrapofadapt001turnsuptheheatontumorsandturnsdowncheckpointblockerresistance AT jeanniewilliams tgfbtrapofadapt001turnsuptheheatontumorsandturnsdowncheckpointblockerresistance AT bryanoronsky tgfbtrapofadapt001turnsuptheheatontumorsandturnsdowncheckpointblockerresistance AT tonyrreid tgfbtrapofadapt001turnsuptheheatontumorsandturnsdowncheckpointblockerresistance AT scottcaroen tgfbtrapofadapt001turnsuptheheatontumorsandturnsdowncheckpointblockerresistance |